Literature DB >> 23402763

European cancer mortality predictions for the year 2013.

M Malvezzi1, P Bertuccio, F Levi, C La Vecchia, E Negri.   

Abstract

BACKGROUND: Estimated cancer mortality statistics were published for the years 2011 and 2012 for the European Union (EU) and its six more populous countries. PATIENTS AND METHODS: Using logarithmic Poisson count data joinpoint models and the World Health Organization mortality and population database, we estimated numbers of deaths and age-standardized (world) mortality rates (ASRs) in 2013 from all cancers and selected cancers.
RESULTS: The 2013 predicted number of cancer deaths in the EU is 1 314 296 (737 747 men and 576 489 women). Between 2009 and 2013, all cancer ASRs are predicted to fall by 6% to 140.1/100 000 in men, and by 4% to 85.3/100 000 in women. The ASRs per 100 000 are 6.6 men and 2.9 women for stomach, 16.7 men and 9.5 women for intestines, 8.0 men and 5.5 women for pancreas, 37.1 men and 13.9 women for lung, 10.5 men for prostate, 14.6 women for breast, and 4.7 for uterine cancer, and 4.2 and 2.6 for leukaemia. Recent trends are favourable except for pancreatic cancer and lung cancer in women.
CONCLUSIONS: Favourable trends will continue in 2013. Pancreatic cancer has become the fourth cause of cancer death in both sexes, while in a few years lung cancer will likely become the first cause of cancer mortality in women as well, overtaking breast cancer.

Entities:  

Mesh:

Year:  2013        PMID: 23402763     DOI: 10.1093/annonc/mdt010

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  111 in total

1.  Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma.

Authors:  Daniel Massó-Vallés; Toni Jauset; Erika Serrano; Nicole M Sodir; Kim Pedersen; Nesrine I Affara; Jonathan R Whitfield; Marie-Eve Beaulieu; Gerard I Evan; Laurence Elias; Joaquín Arribas; Laura Soucek
Journal:  Cancer Res       Date:  2015-04-15       Impact factor: 12.701

2.  Cancer mortality trends between 1988 and 2009 in the metropolitan area of Naples and Caserta, Southern Italy: Results from a joinpoint regression analysis.

Authors:  Anna Crispo; Maddalena Barba; Matteo Malvezzi; Grazia Arpino; Maria Grimaldi; Tiziana Rosso; Emanuela Esposito; Domenico Sergi; Gennaro Ciliberto; Antonio Giordano; Maurizio Montella
Journal:  Cancer Biol Ther       Date:  2013-09-09       Impact factor: 4.742

3.  Addressing cancer disparities in Europe: a multifaceted problem that requires interdisciplinary solutions.

Authors:  Sean Duffy; Mike Richards; Peter Selby; Mark Lawler
Journal:  Oncologist       Date:  2013

4.  Reducing lung cancer and other tobacco-related cancers in Europe: smoking cessation is the key.

Authors:  Luke Clancy
Journal:  Oncologist       Date:  2013-12-06

Review 5.  Market access of cancer drugs in European countries: improving resource allocation.

Authors:  Kim Pauwels; Isabelle Huys; Minne Casteels; Katelijne De Nys; Steven Simoens
Journal:  Target Oncol       Date:  2013-11-19       Impact factor: 4.493

6.  ¹⁸F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.

Authors:  Alexandre Cochet; Inna Dygai-Cochet; Jean-Marc Riedinger; Olivier Humbert; Alina Berriolo-Riedinger; Michel Toubeau; Séverine Guiu; Charles Coutant; Bruno Coudert; Pierre Fumoleau; François Brunotte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-07       Impact factor: 9.236

Review 7.  Perspectives on treatment of metastatic castration-resistant prostate cancer.

Authors:  Axel S Merseburger; Joaquim Bellmunt; Cheryl Jenkins; Chris Parker; John M Fitzpatrick
Journal:  Oncologist       Date:  2013-05-13

Review 8.  Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Davendra P S Sohal; Pamela B Mangu; Alok A Khorana; Manish A Shah; Philip A Philip; Eileen M O'Reilly; Hope E Uronis; Ramesh K Ramanathan; Christopher H Crane; Anitra Engebretson; Joseph T Ruggiero; Mehmet S Copur; Michelle Lau; Susan Urba; Daniel Laheru
Journal:  J Clin Oncol       Date:  2016-05-31       Impact factor: 44.544

Review 9.  First-line therapies in metastatic colorectal cancer: integrating clinical benefit with the costs of drugs.

Authors:  Jacopo Giuliani; Andrea Bonetti
Journal:  Int J Colorectal Dis       Date:  2018-09-08       Impact factor: 2.571

10.  Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.

Authors:  Neil E Bhola; Valerie M Jansen; Sangeeta Bafna; Jennifer M Giltnane; Justin M Balko; Mónica V Estrada; Ingrid Meszoely; Ingrid Mayer; Vandana Abramson; Fei Ye; Melinda Sanders; Teresa C Dugger; Eliezer V Allen; Carlos L Arteaga
Journal:  Cancer Res       Date:  2014-12-05       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.